Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Climb Bio, Inc. (CLYM) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Climb Bio, Inc. is a member of the Medical sector. This group includes 916 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Climb Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CLYM's full-year earnings has moved 10.7% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, CLYM has gained about 143.3% so far this year. Meanwhile, stocks in the Medical group have gained about 2.9% on average. This shows that Climb Bio, Inc. is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Halozyme Therapeutics (HALO). The stock has returned 82% year-to-date.
Over the past three months, Halozyme Therapeutics' consensus EPS estimate for the current year has increased 10.2%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Climb Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 449 individual stocks and currently sits at #98 in the Zacks Industry Rank. On average, this group has gained an average of 2.3% so far this year, meaning that CLYM is performing better in terms of year-to-date returns. Halozyme Therapeutics is also part of the same industry.
Climb Bio, Inc. and Halozyme Therapeutics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Climb Bio, Inc. (CLYM): Free Stock Analysis Report
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).